Life Science REIT (LON:LABS – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat.com reports.
Separately, Jefferies Financial Group reduced their target price on Life Science REIT from GBX 45 ($0.60) to GBX 36 ($0.48) and set a “hold” rating on the stock in a report on Friday, August 30th.
Life Science REIT Trading Up 8.2 %
Featured Stories
- Five stocks we like better than Life Science REIT
- Buy P&G Now, Before It Sets A New All-Time High
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Investing in Commodities: What Are They? How to Invest in Them
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Industrial Products Stocks Investing
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Life Science REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Life Science REIT and related companies with MarketBeat.com's FREE daily email newsletter.